Varex Imaging Corp (VREX) is a United States-based independent supplier of medical X-ray tubes and imaging components. Founded in 2017 and headquartered in Salt Lake City, Utah, VREX is a major player in the Imaging market, engaging in the innovation, designing, and building of X-ray imaging components. It primarily caters to original equipment manufacturers (OEMs) that incorporate these components into their imaging systems that are then used in medical, industrial, and security applications.
Varex Imaging Corp offers a comprehensive suite of products comprising X-ray tubes, digital detectors, software, and other key components of X-ray imaging systems. The company’s technology helps doctors offer better diagnostics and treatments by allowing them to take a closer look inside the human body. It uses advanced industrial imaging technology to detect hidden or unexpected issues in products or systems in non-destructive testing.
VREX operates in two primes segments: Medical and Industrial. The Medical segment designs, manufactures, sells, and services X-ray imaging components mainly for use in various medical imaging applications such as radiographic or fluoroscopic imaging, mammography, computed tomography, radiation therapy, computer-aided detection, and industrial applications. On the other hand, the Industrial segment includes LINAC (linear accelerator) products, security products, and inspection services.
VREX's business model is laudable as it maintains a substantial global footprint with its products used in about 180 countries. Alongside its strong geographic presence, the company's focus on research and development helps them stay at the forefront of the innovation curve. This is evident from their intellectual property portfolio which includes more than 650 patents.
The company's R&D strategies revolve around enhancing its existing products, developing new products to exploit advancements in technology, and expanding into new applications. Having committed partnerships with top OEMs, the company continues to develop new technologies to overcome the challenges of the ever-evolving imaging industry.
In terms of financial performance, Varex Imaging Corp is a publicly traded company listed on the NASDAQ Stock Market under the ticker symbol 'VREX'. Despite the economic challenges presented by the global pandemic, VREX continues to be a solid performer on the financial front addressing the ongoing demands of the medical and industrial imaging sectors.
Overall, Varex Imaging Corp is a powerful force in the healthcare and industrial technology sectors with a proven track record in innovation, high-quality product range, and strong global reach.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Shubham Maheshwari, CFO at Varex Imaging (NASDAQ: VREX), exercised stock options for 160,944 shares worth $783,797, according to a recent SEC filing. The article highlights Varex Imaging's financial health, including its revenue growth, profitability, debt management, and valuation metrics. It also explains the significance of insider transactions for investors.
Varex Imaging Corp Director Jay K. Kunkel sold 8,121 shares of the company's common stock at $18.48 per share on September 14, 2026. This transaction was reported in a Form 4 filing with the SEC on September 15, 2026. Following the sale, Kunkel retains direct ownership of 15,329 shares of Varex Imaging.
Shubham Maheshwari, CFO of Varex Imaging Corp, sold 130,000 shares for approximately $2.4 million after exercising stock options. This "sell-to-cover" transaction occurred as the stock traded near its 52-week high following a significant surge, despite InvestingPro's analysis suggesting it is slightly overvalued. Following these transactions, Maheshwari directly holds 139,972 shares.
Zacks Investment Research recommends VAREX IMAGING (VREX) as a strong value stock due to its favorable Zacks Rank #2 (Buy) and "A" grade for Value. The article highlights VREX's attractive valuation metrics, including a P/E ratio of 12.78, a P/B ratio of 1.08, and a P/S ratio of 0.9, all of which are lower than its industry averages. These indicators suggest that VREX is currently undervalued and possesses a strong earnings outlook.
Pzena Investment Management LLC has acquired a new stake of 4.34 million shares in Varex Imaging (NASDAQ:VREX), valued at approximately $45.31 million, making it a 10.32% owner of the company. Despite Varex beating earnings per share estimates, its revenue fell short, and analysts currently have a cautious "Reduce" rating with a target price below its current trading price. Several other institutional investors also adjusted their holdings in Varex Imaging during recent quarters.